{"organizations": [], "uuid": "3893ee9e4a22a610f5a1d012f845982f451d7b13", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alpine-immune-sciences-provides-co/brief-alpine-immune-sciences-provides-corporate-update-and-reports-full-year-2017-financial-results-idUSASC09TXE", "country": "US", "domain_rank": 408, "title": "BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T14:41:00.000+03:00", "replies_count": 0, "uuid": "3893ee9e4a22a610f5a1d012f845982f451d7b13"}, "author": "", "url": "https://www.reuters.com/article/brief-alpine-immune-sciences-provides-co/brief-alpine-immune-sciences-provides-corporate-update-and-reports-full-year-2017-financial-results-idUSASC09TXE", "ord_in_thread": 0, "title": "BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "alpine immune sciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 45 AM / in 9 minutes BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results Reuters Staff \nMarch 28 (Reuters) - Alpine Immune Sciences Inc: \n* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 FINANCIAL RESULTS \n* ALPINE IMMUNE SCIENCES - EXPECTS TO HAVE CASH TO FUND OPERATIONS INTO 2020, INCLUDING CLINICAL ADVANCEMENT OF ITS LEAD PROGRAMS ALPN-101 AND ALPN-202 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-28T14:41:00.000+03:00", "crawled": "2018-03-28T15:07:07.064+03:00", "highlightTitle": ""}